Author

Thomas E. Witzig

Observed names: T E Witzig, T Witzig, T. E. Witzig, T. Witzig, T.E. Witzig, Witzig, T.E.

Institution: Mayo Clinic

Observed institutions: University of Nebraska at Omaha, Roswell Park Comprehensive Cancer Center, Sunnybrook Health Science Centre, Mayo Clinic, University of Padua, Mayo Clinic in Arizona, Institut Paoli-Calmettes, Odette Cancer Centre

OpenAlex ID: A5108947423

Targeting Apoptosis Pathways in Cancer Therapy

2005 · I. M. Ghobrial, T. E. Witzig, et al. · CA A Cancer Journal for Clinicians · 1,350

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

2011 · L. F. Porrata, K. Ristow, et al. · Haematologica · 208

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney

2009 · M. A. Gertz, N. Leung, et al. · Nephrology Dialysis Transplantation · 127

Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.

2000 · T E Witzig, M Timm, et al. · PubMed · 49

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

2016 · D Rossille, I Azzaoui, et al. · Leukemia · 42

DNA content flow cytometry as a prognostic factor for node-positive breast cancer. The role of multiparameter ploidy analysis and specimen sonication

1991 · T. E. Witzig, N. J. Gonchoroff, et al. · Cancer · 30

Role of Plasmapheresis in Thrombocytopenic Purpura Associated With Waldenström's Macroglobulinemia

1996 · Tushar C. Patel, S. Breanndan Moore, et al. · Mayo Clinic Proceedings · 18

Antibody Therapy for Non-Hodgkin’s Lymphoma

2006 · Stephen M. Ansell, Thomas E. Witzig · Humana Press eBooks · 2

Ps1162 Combination Therapy to Prevent Ibrutinib Withdrawal: Continued Ibrutinib With the Addition of Venetoclax at Time of Progression in Ibrutinib‐treated Patients With Chronic Lymphocytic Leukemia (cll)

2019 · P. Hampel, T. Call, et al. · HemaSphere · 1

Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003)

2009 · M. S. Czuczman, J. Vose, et al. · Journal of Clinical Oncology · 1

224 | Regular Aspirin Use Prior to Diagnosis and Follicular Lymphoma Prognosis: Novel Association With Superior Event‐free Survival

2025 · G. Cholack, R. Mwangi, et al. · Hematological Oncology

The optimized HLH inflammatory index: A novel prognostic tool for newly diagnosed patients with diffuse large B-cell lymphoma—Discovery and validation.

2025 · Adi Zoref Lorenz, Elliot Cahn, et al. · Journal of Clinical Oncology

Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

2024 · Izel Okcu, Arushi Khurana, et al. · Blood

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

2024 · Adi Zoref-Lorenz, Elliot J Cahn, et al. · Blood

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma

2024 · Southey, M.C., Salles, G., et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)

B581 MicroRNA Regulate Growth and Angiogenesis in Multiple Myeloma

2009 · AM Roccaro, MR Melhem, et al. · Clinical Lymphoma & Myeloma

Subcutaneous Interleukin-4 for Relapsed Non-Hodgkin's Lymphoma: A Phase Ii Trial in the North Central Cancer Treatment Group, Ncctg 91-78-51

2007 · D.M. Kurtz, L.K. Tschetter, et al. · Journal of Investigative Medicine

Clinical application of cell kinetics and flow cytometry in the diagnosis and treatment of plasmaproliferative disorders

1990 · T.E. Witzig · Clinical Immunology Newsletter

Works count: 18

Citation count: 1,828

H-index: 7

I10-index: 7